News | December 31, 2025
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Subscribe To Our Newsletter & Stay Updated
